白云山子公司星珠药业药品生产许可证被注销

财中社
Dec 15, 2025

  12月15日,白云山(600332/00874)发布公告,子公司广州白云山星珠药业有限公司的《药品生产许可证》已被注销。注销的原因是星珠药业进行生产经营业务调整,决定在中药饮片的《药品生产许可证》有效期届满后不再申请重新发证。星珠药业在2024年中药饮片业务没有产生营业收入。

  此次注销对公司的影响有限,星珠药业原有其他业务正常开展,因此此次注销不会对其生产经营产生影响,也对公司的当期业绩无重大影响。

  2025年前三季度,白云山实现收入616.06亿元,归母净利润33.10亿元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10